Tyrosine kinase inhibitors used in cancer therapy can have adverse effects, including risks to the eyes, heart, and other systems. The mechanisms of these effects and resistance to the inhibitors are being studied, particularly in relation to certain types of cancer. Guidance is being developed for managing and preventing these adverse effects, which can include cardiotoxicity and other complications.